by Kathy Jones on  March 5, 2013 at 9:06 PM Drug News
 FDA Starts Review of Biogenís Therapy for Hemophilia B
The US Food and Drug Administration is currently reviewing Biogen Idec's application for a fusion protein therapy designed to treat hemophilia B, the company said.

The company revealed that its drug, rFIXFc, has been designed to last longer than currently available drugs and allows patients to endure fewer treatments.

The FDA will be conducting a 10-month review of the drug and is expected to reach a decision in January next year.

Source: Medindia

Most Popular on Medindia